Depression and Survival in Metastatic Non–Small-Cell Lung Cancer: Effects of Early Palliative Care
Open Access
- 20 April 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (12), 1310-1315
- https://doi.org/10.1200/jco.2011.38.3166
Abstract
Purpose In a randomized trial, early palliative care (EPC) in patients with metastatic non–small-cell lung cancer (NSCLC) was observed to improve survival. In a secondary analysis, we explored the hypothesis that the survival benefit resulted from improving depression. Patients and Methods In total, 151 patients with newly diagnosed metastatic NSCLC participated in a randomized trial of EPC integrated with standard oncology care versus standard oncology care alone. Depression was assessed at baseline and at 12 weeks with the Patient Health Questionnaire-9 (PHQ-9) and was scored diagnostically by using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, criteria for major depression syndrome (MDS). Depression response was considered ≥ 50% reduction in PHQ-9 scores at 12 weeks. Survival differences were tested with log-rank and Cox proportional hazards models. Results At baseline, 21 patients (14%) met MDS criteria. MDS significantly predicted worse survival (hazard ratio, 1.82; P = .02). Patients assigned to EPC had greater improvements in PHQ-9 scores at 12 weeks (P < .001); among patients with MDS, those receiving EPC had greater rates of depression response at 12 weeks (P = .04). However, improvement in PHQ-9 scores was not associated with improved survival, except in a sensitivity analysis in which patients who died before 12 weeks were modeled to have worse depression. The group randomly assigned to EPC remained independently associated with survival after adding improvement in PHQ-9 scores to the survival model. Conclusion Depression predicted worse survival in patients with newly diagnosed metastatic NSCLC. Although EPC was associated with greater improvement in depression at 12 weeks, the data do not support the hypothesis that treatment of depression mediated the observed survival benefit from EPC.Keywords
This publication has 24 references indexed in Scilit:
- Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-Small Cell Lung CancerThe Oncologist, 2011
- Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug ApplicationsBritish Journal of Psychology, 2011
- Components of Early Outpatient Palliative Care Consultation in Patients with Metastatic Nonsmall Cell Lung CancerJournal of Palliative Medicine, 2011
- Decrease in Depression Symptoms Is Associated With Longer Survival in Patients With Metastatic Breast Cancer: A Secondary AnalysisJournal of Clinical Oncology, 2011
- Depression and cancer mortality: a meta-analysisPsychological Medicine, 2010
- Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With CancerJournal of Clinical Oncology, 2008
- Depression screening using the Patient Health Questionnaire‐9 administered on a touch screen computerPsycho‐Oncology, 2008
- Negative psychological aspects and survival in lung cancer patientsPsycho‐Oncology, 2007
- The effect of fluoxetine on anxiety and depression symptoms in cancer patientsActa Psychiatrica Scandinavica, 1996
- The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Journal of Personality and Social Psychology, 1986